Nelson Yee, MD
Hematology & Oncology · Hershey, PANPI 1659388999
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,688 of the $13,003 with a category attached, or 74.5%. 20 manufacturers reported payments, led by AstraZeneca at 39.0% of the total. Reporting peaked in 2023 at $4,877 and has fallen 50.9% since, to $2,397 in 2025.
Across 47 payments — averaging $276.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Beone Medicines USA, Inc.$2K
- Taiho Oncology, Inc.$2K
- Bayer$1K
- Daiichi Sankyo Inc.$894
- Beigene USA, Inc.$373
- plus $2K from 14 others
Across 106 payments — averaging $28,839 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$2.4M
- Merck$434K
- Lilly USA, LLC$84K
- Regeneron$42K
- AbbVie$32K
- Pharmacyclics LLC, An Abbvie Company$19K
- plus $7K from 1 others
What the payments were for
- Consulting fees$9,68875%
- Food & beverage$3,17024%
- Education$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $5,072 |
| Beone Medicines USA, Inc. | 1 | $1,940 |
| Taiho Oncology, Inc. | 2 | $1,736 |
| Bayer | 3 | $1,216 |
| Daiichi Sankyo Inc. | 9 | $894 |
| Beigene USA, Inc. | 1 | $373 |
| EMD Serono, Inc. | 4 | $330 |
| E.r. Squibb & Sons, L.L.C. | 3 | $317 |
| Novartis | 2 | $204 |
| Tempus AI, Inc | 2 | $190 |
| Sanofi | 1 | $110 |
| Blueprint Medicines Corporation | 1 | $100 |
| Lilly USA, LLC | 2 | $96 |
| Regeneron | 1 | $84 |
| Intera Oncology, Inc | 1 | $83 |
| Merck | 3 | $77 |
| AbbVie | 1 | $72 |
| GSK | 1 | $67 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,003 in reported general payments places this provider in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 16 | $383,259 |
| StivargaRegorafenib | 19 | $247,553 |
| XermeloTelotristat Etiprate | 11 | $107,488 |
| CreonLipase/Protease/Amylase | 29 | $59,823 |
| Imatinib Mesylate | 68 | $27,753 |
| EliquisApixaban | 15 | $12,033 |
| Octreotide Acetate | 17 | $6,030 |
| Ondansetron Hcl | 124 | $1,676 |
| Oxycodone Hcl | 75 | $1,423 |
| Prochlorperazine Maleate | 45 | $943 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $913 |
| Potassium Chloride | 23 | $451 |
| Ondansetron OdtOndansetron | 12 | $348 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $323 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerStivarga | $1,216 | $247,55319 claims |
| AbbVieCreon | $72 | $59,82329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Hershey
- Kevin RakszawskiHershey$237K
- Chandra BelaniHershey$149K
- Jeffrey PuHershey$103K
- Cristina TruicaHershey$102K
- David NguyenHershey$81K
- Joseph DrabickHershey$53K
- Patrick MaHershey$42K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.